Clinical impact of metformin exposure during Staphylococcus aureus bacteremia in patients with diabetes mellitus
© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature..
PURPOSE: Increasing evidence has suggested that metformin may play positive roles in a wide range of infectious diseases. This study aimed to investigate the clinical impact of metformin exposure during Staphylococcus aureus bacteremia (SAB) in patients with diabetes.
METHODS: A 3-year observational cohort study of 452 patients (aged ≥ 16 years) with SAB was performed at a tertiary care hospital. Metformin exposure was defined as receiving metformin during SAB, regardless of metformin use before the onset of bacteremia.
RESULTS: Of 452 patients, 51 (11.3%) were classified in Group A (diabetes with metformin exposure), 115 (25.4%) in Group B (diabetes without metformin exposure), and 286 (63.3%) in Group C (no diabetes). The 30-day mortality rate in Group A was significantly lower than that in Group B (3.9% [2/51] versus 14.8% [17/115]; p = 0.04) and lower than that in Group C (3.9% [2/51] versus 17.1% [49/286]; p = 0.02). The mortality rates did not differ between Group B and Group C (14.8% [17/115] versus 17.1% [49/286]; p = 0.57). The rates of persistent and recurrent bacteremia were comparable among the three groups. Multivariate analysis indicated that metformin exposure was significantly associated with reduced mortality (adjusted odds ratio, 0.20; 95% confidence interval, 0.04-0.88; p = 0.03).
CONCLUSIONS: Metformin exposure during SAB appears to be an independent predictor of survival in patients with diabetes.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:42 |
|---|---|
| Enthalten in: |
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology - 42(2023), 12 vom: 18. Dez., Seite 1439-1447 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Lee, Ju Young [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Bacteremia |
|---|
| Anmerkungen: |
Date Completed 27.11.2023 Date Revised 27.11.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s10096-023-04679-6 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM363436987 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM363436987 | ||
| 003 | DE-627 | ||
| 005 | 20231226093339.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s10096-023-04679-6 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1211.xml |
| 035 | |a (DE-627)NLM363436987 | ||
| 035 | |a (NLM)37851178 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Lee, Ju Young |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Clinical impact of metformin exposure during Staphylococcus aureus bacteremia in patients with diabetes mellitus |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 27.11.2023 | ||
| 500 | |a Date Revised 27.11.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. | ||
| 520 | |a PURPOSE: Increasing evidence has suggested that metformin may play positive roles in a wide range of infectious diseases. This study aimed to investigate the clinical impact of metformin exposure during Staphylococcus aureus bacteremia (SAB) in patients with diabetes | ||
| 520 | |a METHODS: A 3-year observational cohort study of 452 patients (aged ≥ 16 years) with SAB was performed at a tertiary care hospital. Metformin exposure was defined as receiving metformin during SAB, regardless of metformin use before the onset of bacteremia | ||
| 520 | |a RESULTS: Of 452 patients, 51 (11.3%) were classified in Group A (diabetes with metformin exposure), 115 (25.4%) in Group B (diabetes without metformin exposure), and 286 (63.3%) in Group C (no diabetes). The 30-day mortality rate in Group A was significantly lower than that in Group B (3.9% [2/51] versus 14.8% [17/115]; p = 0.04) and lower than that in Group C (3.9% [2/51] versus 17.1% [49/286]; p = 0.02). The mortality rates did not differ between Group B and Group C (14.8% [17/115] versus 17.1% [49/286]; p = 0.57). The rates of persistent and recurrent bacteremia were comparable among the three groups. Multivariate analysis indicated that metformin exposure was significantly associated with reduced mortality (adjusted odds ratio, 0.20; 95% confidence interval, 0.04-0.88; p = 0.03) | ||
| 520 | |a CONCLUSIONS: Metformin exposure during SAB appears to be an independent predictor of survival in patients with diabetes | ||
| 650 | 4 | |a Observational Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Bacteremia | |
| 650 | 4 | |a Diabetes mellitus | |
| 650 | 4 | |a Metformin | |
| 650 | 4 | |a Staphylococcus aureus | |
| 700 | 1 | |a Kim, Eun Sil |e verfasserin |4 aut | |
| 700 | 1 | |a Chang, Euijin |e verfasserin |4 aut | |
| 700 | 1 | |a Bae, Seongman |e verfasserin |4 aut | |
| 700 | 1 | |a Jung, Jiwon |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Min Jae |e verfasserin |4 aut | |
| 700 | 1 | |a Chong, Yong Pil |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Sung-Han |e verfasserin |4 aut | |
| 700 | 1 | |a Choi, Sang-Ho |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Sang-Oh |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Yang Soo |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology |d 1988 |g 42(2023), 12 vom: 18. Dez., Seite 1439-1447 |w (DE-627)NLM012620742 |x 1435-4373 |7 nnns |
| 773 | 1 | 8 | |g volume:42 |g year:2023 |g number:12 |g day:18 |g month:12 |g pages:1439-1447 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s10096-023-04679-6 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 42 |j 2023 |e 12 |b 18 |c 12 |h 1439-1447 | ||